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AIDS 2009, 23:1443–1451Detectable cerebrospinal fluid HIV RNA with associated neurological deficits, despite suppression of HIV
replication in the plasma compartmentHighly-active antiretroviral therapy (HAART) rapidly
suppresses HIV replication in plasma; however, concerns
exist over the ability of antiretrovirals (ARVs) to penetrate
and suppress viral replication in biological compartments
such as the central nervous system (CNS) and genital tract
[1,2]. Ongoing cerebrospinal fluid (CSF) HIV replication
in the presence of virological suppression in the plasma
compartment by HAART is not well described [3]. We
describe the case of an individual treated with HAART,
successfully maintaining plasma HIV RNA below
50 copies/ml, who had ongoing CSF HIV replication
with neurological symptoms.
A 33-year-old white man presented with left leg weakness
affecting his gait. An HIV test 6 months earlier was nega-
tive. Neurological examination demonstrated increased
tone, sustained ankle clonus, pyramidal distribution
weakness (Medical Research Council grade 4/5), brisk
reflexes and an extensor plantar response affecting the left
leg, with normal findings elsewhere.
Cerebral MRI revealed a nonenhancing right precentral
gyrus lesion (Fig. 1). CSF contained 13 mononuclear
cells/ml, protein 0.4 g/l, glucose 3.6 mmol/l (serum
5.2 mmol/l), and viral PCRs (John Cunningham virus,
herpes simplex virus, varicella-zoster virus, Epstein–Barr
virus, enterovirus and cytomegalovirus) were negative, as
were CSF tests for cryptococcal antigen, syphilis and
culture for bacteria, fungi and tuberculosis. Investigations
found no obvious cause for a cerebrovascular event.
Serum was positive for HIV-1 antibody, CD4 cell count
was 190 cells/ml (27%), plasma HIV viral load was
361 837 copies/ml and human leukocyte antigen-B5701
allele test was negative. Genotypic analysis of plasma
revealed wild-type virus (clade B) [4].
A clinical diagnosis of recent HIV seroconversion with
neurological involvement was made. The patient was
commenced on HAART [abacavir, lamivudine (Kivexa)
and saquinavir/ritonavir], and plasma HIV RNA of less
than 50 copies/ml was achieved by week 12. Follow-up
cerebral MRI was unchanged 3 and 6 months later.
Twelve months later, the patient experienced worsening
of left leg weakness. HAART was unchanged, plasma
HIV RNA was consistently less than 50 copies/ml and
CD4 cell count had risen to 450 cells/ml (47%). MRI
revealed additional diffuse-enhancing lesions throughout
both cerebral hemispheres. CSF white cell count was fouropyright © Lippincott Williams & Wilkins. Unauth
ISSN 0269-9370 Q 2009 Wolters Kluwer Heaper microliter, and the CSF HIV RNA level was
718 copies/ml.
Two months later, plasma HIV RNA remained less than
50 copies/ml, and CSF HIV RNA was 676 copies/ml.
CSF sequencing of reverse transcriptase/polymerase
confirmed clade B HIV-1 virus, and M184V and
D67E were observed. Furthermore, the CSF on this
occasion contained 44 mononuclear cells/ml, protein
0.53 g/l and glucose 3.2 mmol/l (serum 5.2 mmol/l).
Tuberculosis culture and all other CSF tests were negative.
HAART was switched to abacavir, zidovudine, lamivu-
dine (Trizivir) and nevirapine [200 mg twice daily (b.i.d)]
with the aim of improving CNS penetration of ARV
agents. MRI performed 3 months later showed that the
prefrontal gyrus lesion was unchanged; however, the small
enhancing lesions had resolved. The CSF pleocytosis had
fully resolved, and CSF HIV viral load was now less than
50 copies/ml.
The case demonstrates the ability of HIV to continue
replicating within the CNS compartment, despite the
plasma viral load being suppressed by HAART to below
50 copies/ml. This phenomenon has not previously
been well described. Along with other investigations,
CSF HIV RNA quantification and genotype should
be considered early in any individual with neuro-
logical symptoms, irrespective of plasma HIV RNA
level.
Further research will establish optimal ARV combinations
for such individuals and demonstrate whether longitudi-
nal monitoring of CSF RNA and genotype (with
HAART adjustment accordingly) can benefit clinical
outcome. The work conducted by Letendre et al. [5]
demonstrated the use of a CNS penetration efficacy
ranking score (based on available data of ARV chemical
properties, concentration in the CSF and/or results in
clinical studies) that is associated with a lower level of CSF
HIV RNA. Long-term clinical outcome data for this
strategy, however, do not yet exist.
Of interest, our patient developed a late CSF pleocytosis
without evidence of additional CNS infections, and after
changing HAART, this resolved. It is possible that CNS
inflammation developed in response to persistent
HIV replication and resolved with ‘CNS-optimized’
HAART. This mechanism maybe similar to the brief CSForized reproduction of this article is prohibited.
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Fig. 1. T2-weighted flair image demonstrating enhancing
lesion in the right precentral gyrus.pleocytosis demonstrated in approximately half of the
patients on stopping therapy [6].
The shortcomings of this report include that ultrasensitive
techniques were not used for HIV RNA quantification,
and minority level resistance mutations may have been
present in plasma at baseline. Furthermore, CSF HIV
RNA and genotype were not performed at baseline and,
therefore, it cannot be confirmed that the CSF HIV
resistance mutations that developed were due to the
therapy administered.
Clinicians managing individuals with neurological symp-
toms and an undetectable plasma HIV RNA should be
aware of the possibility of CSF virological replication and
the selection of viral variants associated with drug
resistance.
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DOI:10.1097/QAD.0b013e32832d077cAre the effects of isoniazid preventive therapy and highly active antiretroviral therapy additive in preventing
HIV-associated tuberculosis?Golub et al. [1] recently reported a retrospective analysis of
rates of incident tuberculosis (TB) in a large observational
cohort of 2778 patients accessing HIV care in rural
and urban South Africa. The TB incidence rate was
highest [7.1/100 person-years; 95% confidence interval
(CI)¼ 6.2–8.2] during the period of care when patients
did not receive isoniazid preventive therapy (IPT) or highly
active antiretroviral therapy (HAART). The rates were
lower during person-time that accrued throughout
follow-up after initiation of IPT (5.2/100 person-years;95% CI¼ 3.4–7.8) and throughout follow-up on
HAART alone (4.6/100 person-years, 95% CI¼ 3.4–
6.2). The rate was lower still (1.1/100 person-years
95% CI¼ 0.2–7.6) during person-time accrued during
sequential IPT and HAART (IPTþHAART). The
authors concluded that TB risk was significantly reduced
by IPT in HAART-treated adults. It was further concluded
that ‘the dramatic reduction in TB risk’ demonstrated in
this study together with supportive data from a similarly
analysed study from Brazil [2] indicates that widespread useized reproduction of this article is prohibited.
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roll-out of HAART.
First, it is notable that HAART alone but not IPT alone
was associated with significantly lower TB incidence rates
compared with the nonintervention group in both
adjusted and unadjusted analyses. In addition, no sig-
nificant difference was observed in the incidence rates
comparing the HAART-only and the IPTþHAART
groups. Thus, these analyses do not demonstrate a sig-
nificant additive effect in TB prevention by treating
patients with both IPT and HAART.
In further analysis, Kaplan–Meier survival estimates
appeared to support a significant difference between TB-
free survival in the IPTþHAART group and all other
treatment groups. Surprisingly, however, the Kaplan–
Meier analysis showed that no TB events occurred among
patients in the IPTþHAART group during the first
3 years of observation despite low CD4 cell counts
(median, 176 cells/ml at the time of HAART initiation).
We are concerned that these conclusions may have been
erroneously drawn as a result of analysis of groups with
significant selection bias.
Among 62 patients within the IPTþHAART group, 61
had initiated IPT for a median of 1.0 years [interquartile
range (IQR)¼ 0.5–1.9] before starting HAART. In this
analysis, person-time of observation was censored when
patients developed TB. Thus, only selected patients who
remained alive and free of TB during the period between
IPT initiation and HAART initiation would be eligible
for inclusion in the IPTþHAART group. Thus, the TB
incidence rate during the median of 1.0 years (IQR 0.5–
1.9) of observation before HAART would have been
inappropriately assessed as zero cases/100 person-years.
However, the IPTþHAART group had markedly lower
CD4 cell counts than the IPT-alone group and therefore
the true incidence rate would very likely have exceeded
5.2 cases/100 person-years in the pre-ART period, poten-
tially adding several more cases to the single case actually
reported in this treatment group. Furthermore, no deaths
were reported in this survival analysis and additional cases
of TB may well have remained unascertained among those
who died. Inclusion of such additional TB cases would
likely have negated the apparent observed group differ-
ences in the Kaplan–Meier analysis.
The benefits of IPT in HIV-infected patients included in
randomized controlled trials have been clearly demon-
strated [3,4]. However, the lack of significant effectiveness
of IPT alone in this South African study and in the large
Brazilian cohort study [2] raises concerns about the
effectiveness of this intervention in routine clinical prac-
tice. Potential explanations for lack of IPT efficacy may
include poor adherence and the inclusion of tuberculin
skin test-negative individuals. However, in both these
studies, the strongest predictor of TB incidence rates wasopyright © Lippincott Williams & Wilkins. Unauththe baseline CD4 cell count, with 60–90% lower rates in
those with CD4 cell strata above 200 cells/ml. Further-
more, there are no data from randomized controlled trials
that specifically demonstrate the efficacy of primary IPT
at low CD4 cell counts. We wonder, therefore, whether
the inclusion of significant numbers of individuals with
CD4 cell counts under 200 cells/ml may partially explain
the apparent lack of a statistically significant reduction of
TB rates during and after IPT.
In view of the clear benefits of HAART on survival and
TB incidence [5], it would be unethical to perform
studies of 6 months IPT or placebo before initiating
HAART in eligible patients. TB rates during early
HAART are very high and related to the baseline CD4
cell count at treatment initiation, remain high in those
with suboptimal CD4 cell recovery and continue to be
elevated even in those with optimal CD4 cell recovery
[6–8]. There remains an urgent need to demonstrate an
additive benefit of IPTover and above CD4 cell recovery
after initiation of HAART and to identify the optimal
timing of IPT before this can be scientifically justified as
an integrated component of HAART rollout.Acknowledgements
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DOI:10.1097/QAD.0b013e32832d53e7Additive effects of isoniazid preventive therapy and HAARTOur thanks to Wood et al. [1] for their interest in our study
describing the benefits of isoniazid preventive therapy
(IPT) and highly active antiretroviral therapy (HAART) for
HIV-infected patients being followed prospectively in
South Africa [2]. Tuberculosis is an exceedingly common
opportunistic infection and the leading cause of death in
HIV-infected adults, irrespective of their HAART treat-
ment status. Given that the effectiveness of IPT has been
clearly demonstrated in multiple trials and cohort analyses
[3] but its uptake incredibly poor in resource-limited
settings [4], we were interested inunderstanding the impact
of both HAART and IPT in a clinical cohort in South
Africa, a very high-burden area. As clearly stated in our
study, clinical cohort studies are subject to a number of
limitations and potential biases that are not present in
randomized trials. Conversely, however, clinical cohorts
represent a much more real life situation than clinical trials,
in which patients are not excluded because of comorbid
conditions and adherence to protocols is imperfect. We
endeavored to learn the most from our data by constructing
analyses that minimized potential biases and adjusted for
important covariates, including time and CD4 cell counts.
We believe that Wood et al. [1] may have misunderstood
some of these analytical methods in their critique of
our results.
First, we were careful to categorize all follow-up time into
four categories according to exposure to IPT and/or
HAART: treatment naive, IPT only, HAART only, and
both IPTand HAART – the majority of whom received
IPT prior to receiving HAART. Thus, we compared the
incidence of tuberculosis during treatment-naive follow-
up with the incidence in each of the different treatment
categories and did not use time accrued in a different
category in our calculations. For example, the patients
who received both IPT then HAART (without being
censored) contributed person time to three categories
(treatment naive, IPT only, and IPT/HAART), and any
tuberculosis event would be attributed to the IPT/
HAART time period. The simple rate calculations based
on these person-years can be affected by survival bias,
with person-years in one exposure group tending to beearlier during follow up than those exposed to both. For
the Kaplan–Meier and Cox models, however, all patients
followed a time-since-cohort entry timeline, with
staggered entry according to category transitions. Thus,
for example, a patient who has been followed for exactly 2
years and is on both IPTand HAART is compared at that
instant with all the rest who also have survived (not been
censored) at least 2 years. We did not directly compare
patients receiving HAART with those receiving both
IPT and HAART; the incidence within each of these
time periods was compared with the incidence among
treatment-naive patients. What our data show, therefore,
is that the point estimate of tuberculosis incidence for
those who received both IPTand HAART is considerably
lower than for those who received either intervention
alone, suggesting an interaction between these two inter-
ventions.
As noted by Wood et al. [1], CD4 cell counts are important
potential confounders in an analysis such as ours, and we
adjusted for baseline CD4 cell counts accordingly. The
median CD4 cell count at time of IPT for everyone
receiving IPT, including thosewho later receivedHAART,
was 399 cells/ml. Patientswho receivedHAART following
IPThadamedianCD4cellcountof176 cells/ml atHAART
initiation, similar to those patients who received HAART
and no IPT (median CD4 cell count, 145 cells/ml). Our
adjusted Cox proportional hazards model revealed that
patients receivingboth IPTand HAART had a significantly
reduced risk of tuberculosis after adjustment for baseline
CD4 cell count (89% reduction). The protective effect of
HAARTonly compared with treatment-naive patients was
significant as well (64% reduction). As stated above, these
estimates cannot be directly compared in our analysis, but
clearly suggest that patients receiving both therapies have
greater protection.
Wood et al. [1] also wonder whether IPT alone was not
significantly associated with protection from tuberculosis
because of the inclusion of many patients with CD4 cell
counts less than 200 cells/ml. When we examined only
patients with baseline CD4 cell count more thanized reproduction of this article is prohibited.
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better than in our overall model [adjusted hazards ratio
(aHR)¼ 0.81; 95% confidence interval (CI)¼ 0.48–1.38
versus overall aHR¼ 0.87; 95% CI¼ 0.55–1.36].
As noted by Wood et al. [1], the benefits of IPT have been
clearly established, and its use is recommended by the
WHO. Although it is also clear that HAART reduces the
risk of tuberculosis, rates are more than 10-fold higher
than in HIV-uninfected individuals, and our data suggest
that IPT can further reduce this risk. Although it is
reasonable to study whether IPT significantly improves
protection compared with HAARTalone in patients with
advanced HIV infection, we do not believe that it is
appropriate to withhold IPT from patients in HAART
roll-out programs pending the results of studies. By
analogy, when HAART was first introduced and its
benefits were being appreciated, guidelines for prevention
of opportunistic infections remained in place, including
the use of cotrimoxazole and azithromycin. Only when
controlled trials demonstrated that these therapies were
not necessary following a response to HAART did the
guidelines change. If clinical trials were to show that there
is no additional benefit to IPT in patients receiving
HAART (and we are skeptical of this), then Wood et al.
[1] would be justified in recommending that IPT be
omitted from HAART treatment programs. In the
meanwhile, ignoring the results of controlled trials with
more than 11 000 participants and the results of cohort
studies with approximately 15 000 participants [2,5]
showing the benefits of IPT means that millions of
patients are exposed to an unjustified risk.opyright © Lippincott Williams & Wilkins. UnauthJonathan E. Goluba,b, Richard E. Chaissona,b and Neil
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DOI:10.1097/QAD.0b013e32832d53fcIdiopathic central pontine myelinolysis in an eunatremic patient with AIDSCentral pontine myelinolysis (CPM) is an uncommon
condition usually seen in patients with underlying condi-
tions such as chronic alcoholism, malignancy, malnutrition,
and hyponatremia [1]. We recently encountered a patient
with AIDS and neurological abnormalities, whose evalua-
tion was consistent with CPM.
A 38-year-old female patient with AIDS (most recent
absolute CD4 cell count of 14 cells/ml) presented with
a 4-week history of dysarthria, dysphagia, increasing
generalized weakness, blurred vision, confusion, and diffi-
culties with balance and walking. She was noncompliant
with her prescribed medications (lopinavir/ritonavir
400 mg/100 mg twice daily, emtricitabine 200 mg daily,
tenofovir 300 mg daily, atovaquone 1500 mg daily, and
azithromycin 1200 mg weekly).
She was apyrexic with a blood pressure of 74/40 mmHg,
a pulse of 102 beats/min, and a respiratory rate of
22 breaths/min. Oxygen saturation was 96% whilebreathing room air. There was no detectable lymphade-
nopathy or hepatosplenomegaly. Neurological examin-
ation was notable for horizontal nystagmus, dysarthria,
ataxia, dysdiadokokinesia, and reduced muscle strength in
the upper and lower extremities. Otherwise, the physical
examination was unremarkable.
The results of a complete blood count, renal and hepatic
function tests, and serum albumin and electrolyte values
were normal as they had been on multiple occasions over
the preceding several years. Magnetic resonance imaging
(MRI) of the brain revealed diffuse edema in the pons,
except for the dorsal aspect, consistent with CPM (Fig. 1).
Cerebrospinal fluid (CSF) examination revealed one white
blood cell and two red blood cells, glucose of 72 mg/dl,
protein of 29 mg/dl, a nonreactive Venereal Disease
Research Laboratory test, and a negative cryptococcal
antigen assay. DNA amplification, by polymerase chain
reaction, performed on the CSF was negative for toxo-
plasma, herpesviruses 1 and 2, cytomegalovirus, BK virus,orized reproduction of this article is prohibited.
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Fig. 1. Magnetic resonance imaging of the brain with a well
defined lesion in the pons of low T1-signal intensity (white
arrow) consistent with central pontine myelinolysis.and JC virus. CSF did not demonstrate oligoclonal bands
suggestive of multiple sclerosis. Histoplasma antigen was not
detected in the urine.
Empiric therapy for toxoplasmosis was begun, and her
other medications were continued. She was discharged
home but readmitted 1 month later with continued
neurological decline. A repeat MRI of the head was
again consistent with CPM, and other evaluation was
unremarkable. Her neurological condition failed to
improve, and she was ultimately transferred to a long-
term care facility for terminal care. She continued with
a decline in overall function and expired 3 months
following her diagnosis with CPM. Permission for autopsy
was not granted.
CPM is a demyelinization syndrome of the pons, which
may be seen with rapid correction of hyponatremia [2]
or other underlying conditions such as malnutrition,
malignancy, alcoholism, burn injury, and chronic renal
failure [1,3]. Severe neurological symptoms may result.
Diagnosis is usually made at autopsy or on the basis of
imaging studies.
The rare reports of CPM occurring in AIDS patients
usually include other conditions that increase the poten-
tial for development of CPM [1,3–8]. The two patients
described by Miller et al. [1] both had Kaposi sarcoma:
one was found at autopsy to have lymphoma, and one had
a history of heavy alcohol consumption. Holmes et al. [6]
reported a case of CPM in an AIDS patient without
preexistent hyponatremia [6]. Their patient, however,
had prolonged hypoalbuminemia. By contrast, our patient
was not known to have been hyponatremic or hypoalbu-
minemic or to have another identified condition known to
be associated with CPM.pyright © Lippincott Williams & Wilkins. UnauthorCPM in patients with HIV infection may not be
recognized in life [1,5,6,8]. Clinical presentation may
vary, ranging from mutism and dysarthria to spastic
quadriparesis with a pseudobulbar palsy [2]. Lethargy and
affective changes are common. Outcome is variable,
ranging from complete recovery to death. Improvement
may be gradual or partial with persisting bulbar dys-
function and spastic quadriparesis [2].
Our case illustrates that CPM should be considered as the
cause for neurological disease in patients with AIDS
in the appropriate clinical setting, regardless of serum
sodium and albumin levels, especially if other diagnoses
are excluded. If hyponatremia exists, caution should be
exercised in its correction.Acknowledgements
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DOI:10.1097/QAD.0b013e32832d8f0aDisruption of an env tyrosine-dependent sorting signal does not affect susceptibility of HIV-1 to cytotoxic
T lymphocytesInfections with live-attenuated viruses within SIV models
of HIV-1 pathogenesis have offered the best evidence that
a vaccine could generate protective immunity. Daniel
et al. [1] first demonstrated this principle using nef-
defective SIV, which established a chronic low-grade
asymptomatic infection in macaques associated with
protection against subsequent challenge with wild-type
SIV. At least in part, this phenomenon appeared to be due
to attenuation of viral replication.
More recently, Shacklett et al. [2] and Fultz et al. [3] have
examined attenuated SIV infection through mutations
in the transmembrane domain of gp41, which also
subsequently protect from challenge by wild-type SIV.
Shacklett et al. found that SIV containing multiple (stop
and point) mutations disrupting this domain reduced viral
replicative capacity in vitro, likely due to effects on gp41
membrane trafficking in infected cells [4,5]. Fultz et al.
more specifically created mutations in the tyrosine-based
sorting motif (Y712xxf) in the membrane-proximal
cytoplasmic domain of gp41 [3]. Despite the role this
motif in gp41 trafficking [4,5], the mutations appeared to
have minimal impact on viral fitness, reflected by normal
peak viremia during acute infection in vivo and growth
kinetics in vitro. Thus, the mechanism of attenuation and
subsequent immune protection is unclear, but probably
not due to markedly reduced viral replication capacity.
Interestingly, in-vivo CD8 depletion experiments have
suggested that CD8þ T lymphocytes (CTLs) may con-
tribute to the protective immunity [6].
To assess whether analogous mutations in HIV-1 might
affect viral susceptibility to CTLs, mutations in the
Y712xxf motif were constructed in HIV-1 NL4-3 [7] by
point mutagenesis (QuikChange, Stratagene). These
included EnvY712I, EnvY712S and EnvDGY mutations
in the cytoplasmic domain of gp41 (Fig. 1a), engineered
into the whole genome context of NL4-3.1 containing
the clade B consensus sequence at Gag 77-85 (HXB2
amino acid numbering) [8]. These viruses were examined
for their ability to replicate in T1 cells [9] (Fig. 1b). The
EnvY712I and EnvY712S mutants had growth kinetics
similar to those of wild-type NL4-3 (EnvY712), in turn
similar to SIVmac239 [3]. In contrast, the EnvDGY
mutant was replication incompetent, suggesting that this
mutation more severely impaired HIV-1 than SIV.
To assess the susceptibility of these mutants to CTLs, these
viruses were tested in virus suppression assays [10,11]
using HIV-1-specific CTL clones: S1-SL9-3.23T recog-nizing the HLA A02-restricted epitope SLYNTVATL in
Gag p17 (amino acid 77–85) [12], S31-IV9-10.11T
recognizing the HLA A02-restricted epitope ILK-
EPVHGV in reverse transcriptase (amino acid 309–317)
and S58-PL10-10.8 recognizing the HLA A02-
restricted epitope PLTFGWCYKL in Nef (amino acid
136–145). The HIV-1-permissive target cells were A02-
expressing T1 cells [10]. Comparisons of these viruses
showed similar degrees of suppression of the mutant and
wild-type viruses by the three CTL clones (Fig. 1c and d).
Similar results were noted in independent experiments
using two other CTL clones recognizing other epitopes
(not shown). Overall, these results suggested that directly
increased susceptibility to CTL inhibition is not the
mechanism of in-vivo attenuation of infection with
viruses containing these mutations.
Because attenuated SIV infection has been the most
robust example of protective vaccination in the SIV
macaque model [1,6,13–15], understanding how viral
attenuation affects antiviral immunity is clearly an
important goal. The observation that SIV mutated in
the Y712xxf motif yields infections with typical high
peak viremia followed by chronic low viremia in
macaques subsequently protected from wild-type virus
challenge [2,3,6] suggests that viral replication is not
markedly affected by the mutations, but that replication is
suppressed during chronic infection after development of
CTL responses, which are the major determinant of set-
point viremia [16–18]. Furthermore, preliminary data
suggest that the low set-point viremia of macaques
infected with Y712xxf-disrupted SIV may be related to
the CTL response [6]. Thus, a simple explanation could
be that disruption of this motif somehow renders SIV
directly more susceptible to CTL.
However, our results suggest that this is not the case for
HIV-1; disruption of the Y712xxf motif did not appear
to increase susceptibility of HIV-1 to CTLs directly.
Although our in-vitro assay may not necessarily predict
the interaction of virus and CTLs in vivo, it seems likely
that the mechanism of attenuation is either not mediated
by CTLs, or indirectly increases the antiviral activity of
CTLs. Interestingly, it has been suggested that the HIV-1
Env may facilitate viral escape from CTLs in lymph nodes
[19,20]. Although our data do not address this issue
directly, they are compatible with a mechanism whereby
reduced levels of Env could reduce viral escape from
CTLs. Further work would be required to explore
this possibility.orized reproduction of this article is prohibited.
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Fig. 1. Susceptibility of Env Y712xxf motif mutant viruses to HIV-1-specific CD8R T lymphocyte. (a) Nucleotide (NL4-3 residues
8355–8369) and amino acid (NL4-3 Env residues 711–715) sequences are given for the wild-type NL4-3.1 virus and generated
mutants. Dash (–) indicates the same nucleotide or amino acid as wild type and cross () indicates a deletion of a nucleotide or
amino acid compared with wild type. (b) 1 106 HIV-1 permissive T1 cells were infected with the indicated mutant or wild-type
virus at an input of 1000 pg p24 antigen and cultured in a 24-well tissue culture plate. Viral replication was measured by
quantitative p24 ELISA (Perkin–Elmer, Waltham, Massachusetts, USA). These results are representative of four independent
experiments. (c) T1 cells were infected with 500 pg p24/106 cells and cultured in triplicate in 96-well tissue culture plates with the
indicated CD8þ T lymphocyte (CTL) clones (1.25104 CTLs with 5104 target cells). Viral replication was measured by
quantitative p24 ELISA (Perkin–Elmer) on day 4 after infection. (d) Inhibition was calculated by comparing replication in cells with
or without CTLs. The plotted data indicate means of triplicates (error bars indicate 1 SD) for one experiment, and the results are
representative of two independent experiments with these clones. Similar results were seen using a B57-restricted CTL clone
recognizing the epitope TSTLQEQIGW in Gag p24 and an A02-restricted CTL clone recognizing the epitope AIIRILQQL in Vpr in
other experiments (data not shown).Acknowledgement
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